Stockreport

Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF – Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver –– February 21, 2020 PDUFA Targe [Read more]